Myriad Genetics Inc
XBER:MYD

Watchlist Manager
Myriad Genetics Inc Logo
Myriad Genetics Inc
XBER:MYD
Watchlist
Price: 5.65 EUR -3.42% Market Closed
Market Cap: 507.9m EUR

Wall Street
Price Targets

MYD Price Targets Summary
Myriad Genetics Inc

Wall Street analysts forecast MYD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MYD is 6.96 EUR with a low forecast of 2.99 EUR and a high forecast of 15.99 EUR.

Lowest
Price Target
2.99 EUR
47% Downside
Average
Price Target
6.96 EUR
23% Upside
Highest
Price Target
15.99 EUR
183% Upside
Myriad Genetics Inc Competitors:
Price Targets
1801
Innovent Biologics Inc
31% Upside
DTIL
Precision BioSciences Inc
638% Upside
KNSA
Kiniksa Pharmaceuticals Ltd
29% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
50% Upside
CHRS
Coherus BioSciences Inc
325% Upside
HALO
Halozyme Therapeutics Inc
15% Upside
603087
Gan & Lee Pharmaceuticals
4% Downside
KRYS
Krystal Biotech Inc
6% Downside

Revenue
Forecast

Revenue Estimate
Myriad Genetics Inc

For the last 3 years the compound annual growth rate for Myriad Genetics Inc's revenue is 7%. The projected CAGR for the next 4 years is 4%.

7%
Past Growth
4%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Myriad Genetics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Myriad Genetics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MYD's stock price target?
Price Target
6.96 EUR

According to Wall Street analysts, the average 1-year price target for MYD is 6.96 EUR with a low forecast of 2.99 EUR and a high forecast of 15.99 EUR.

What is Myriad Genetics Inc's Revenue forecast?
Projected CAGR
4%

For the last 3 years the compound annual growth rate for Myriad Genetics Inc's revenue is 7%. The projected CAGR for the next 4 years is 4%.

Back to Top